REF: 1. Molloy JW, Stengel JZ and Arnold HL (2009) Infliximab: A Review of its use in the treatment of Crohn’s Disease. Clinical Medicine. Therapeutics. 2. Rutgeerts P, Van Assche G and Vermeire S (2006) Review article: Infliximab therapy for inflammatory bowel disease – seven years on. Alimentary Pharmacology & Therapeutics, 23:451-463.3. Cha JM et al. Journal Korean Med Sci (2017); 32:85-9
Remsima® SC (infliximab) provides an alternative treatment option for patients with PsA, PSO, RA, CD, UC, and AS.1,2
Remsima® SC is indicated for the treatment of adult patients with moderate to severe plaque psoriasis for whom phototherapy or conventional systemic treatments have been inadequate or are inappropriate1.
The availability of infliximab IV and a subcutaneous formulation of Remsima® provides a treatment approach tailored to the individual needs of your patients.
Remsima® SC can be an expanded treatment option with comparable efficacy and safety to infliximab IV.3,4
Available in a pre-filled pen and pre-filled syringe with needle guard
Remsima® 120 mg solution for injection in pre-filled pen
Remsima® 120 mg solution for injection in pre-filled syringe with needle guard
| PBS Information: Authority required for the treatment of adults with severe chronic plaque psoriasis. Refer to the PBS Schedule for full authority information. |
Before prescribing, please review full Product Information available on request from the Celltrion Healthcare Medical Information Service (Phone: 1800 325 228) or www.ebs.tga.gov.au
AS, ankylosing spondylitis; CD, Crohn’s disease; IV, intravenous; PSA, psoriatic arthritis; PSO, plaque psoriasis; RA, rheumatoid arthritis; SC, subcutaneous; UC, ulcerative colitis
References: 1. Remsima® Approved Australian Product Information available at https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2020-PI-02558-1&d=20230223172310101. Last Accessed on 06.09.2024. 2. The Pharmaceutical Benefit Scheme available at www.pbs.gov.au. 3. Schreiber, S et al. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease; J. Gastroenterol. DOI: https://doi.org/10.1053/j.gastro.2021.02.068 Accessed 27.08.2024. 4. Westhovens et al. Efficacy pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial. Rheumatology 2021;60:2277-2287. 5. Celltrion Data on File (REF-00354 Jan 2023). 6. European Medicines Agency. Guidelines on Similar Biological Medicinal Product containing biotechnology derived proteins. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues-revision-1_en.pdf Last accessed: 06.09.2024. 7. Australian Government Department of Health Therapeutic Goods Administration. Biosimilar Medicines Regulation. Version 2.2. April 2018. Available at: https://www.tga.gov.au/sites/default/files/biosimilar-medicines-regulation.pdf Last accessed: 06.09.2024. 8. Australian Government Department of Health. Available at: https://www.health.gov.au/sites/default/files/documents/2022/04/biosimilar-medicines-the-basics-for-healthcare-professionals.pdf Last Accessed: 06.09.2024. 9. Jørgensen K, Olsen I, Goll G, et al. NOR-SWITCH study group. The Lancet. 2017;389(10086):2304-2316. 10. Goll G, Jørgensen K, Sexton J, Olsen I, et al. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open label extension of the NOR-SWITCH trial. J Intern Med 2019; 285: 653–669. 11. Cha JM et al. Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients. Journal Korean Med Sci 2017; 32:85–94.